Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance
HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and nine months ended September 30, 2017 . Third Quarter 2017 Financial Highlights Total revenues of $2.99 billion , down 2% compared to the
View HTML
Toggle Summary Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting
Presentations Highlight 24-Hour Serial Spirometry Subgroup Findings from Two Replicate Pivotal Phase 3 Studies; Improvements Observed in St. George's Respiratory Questionnaire and COPD Assessment Test Results
View HTML
Toggle Summary Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint
HERTFORDSHIRE, England and PITTSBURGH , Oct. 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) provided the following statement in response to the announcement of proposed amendments to the civil complaint by various states' attorneys general in multi-district litigation pending in the U.S.
View HTML
Toggle Summary Mylan's EpiPen4Schools® Program Surpasses One Million Free Epinephrine Auto-Injector Donations to U.S. Schools
- 2017 marks the five-year anniversary of Mylan's EpiPen4Schools® program.- New data presented at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting showed that more than 1,500 anaphylactic events were reported in the 2015-2016 school year, and nearly 60% of the time an epinephrine auto-injector was used, it was an EpiPen® (epinephrine injection, USP) Auto-Injector donated by the EpiPen4Schools program.- Nearly one-third (30%) of individuals experiencing anaphylaxis had no previously known allergies.
View HTML
Toggle Summary Mylan Wins UK Court Ruling Related to Copaxone® 40 mg/mL Patent
HERTFORDSHIRE, England and PITTSBURGH , Oct. 26, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United Kingdom's High Court of Justice has issued a decision in favor of Mylan and its European partner Synthon , finding all claims of Teva's patent EP ( UK ) 2 949 335 (EP
View HTML
Toggle Summary Mylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017
HERTFORDSHIRE, England and PITTSBURGH , Oct. 17, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Monday, Nov. 6, 2017 , at 10:30 a.m. ET , to review the company's financial results for the third quarter ended Sept.
View HTML
Toggle Summary Mylan Invalidates Allergan's Patents on Restasis®
HERTFORDSHIRE, England , and PITTSBURGH , Oct. 16, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of the patents relating to Restasis® invalid
View HTML
Toggle Summary Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mL
Mylan Has Exclusive Rights for Glatiramer Acetate in Several Key European Markets
View HTML
Toggle Summary Mylan Launches First AP-rated Generic Avelox® Injection
HERTFORDSHIRE, England and PITTSBURGH , Oct. 5, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 250 mL single-dose flexible bags, the first AP-rated generic version of
View HTML
Toggle Summary Mylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and Generic for Copaxone® 20 mg/mL Once-Daily
HERTFORDSHIRE, England , and PITTSBURGH , Oct. 4, 2017 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the company has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated substitutable generic version of Teva's
View HTML